Growth slowing at Reckitt Benckiser

Have your say

HOUSEHOLD products giant Reckitt Benckiser warned of slower growth due to a number of one-off effects, as the company matched forecasts with a nine per cent rise in third-quarter earnings.

The maker of Cillit Bang cleaners and Nurofen painkillers also cautioned that its new “film” version of its Suboxone heroin substitute drug had gained just 44 per cent of its market, showing that its recent growth in market share has stalled.

The company has a personal care manufacturing site in Hull, which is used to produce Gaviscon heartburn medicine, Nurofen pain relief tablets for children, Lemsip cold remedy and Dettol cleaner.

Together with its research and development site which is also situated in the city, it employs about 500 staff in Hull.

The group, which also makes Air Wick air fresheners, Vanish fabric cleaners and Finish dishwash products, said it is well positioned to achieve its 2011 targets of a 12 per cent rise in net revenue and a 10 per cent rise in net income growth, helped by the purchase late last year of Durex condom and Scholl sandal maker SSL.